niacinamide has been researched along with Gallbladder Neoplasms in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Gallbladder Neoplasms: Tumors or cancer of the gallbladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study." | 9.19 | Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. ( Berie, L; Denzer, U; Distelrath, A; Dollinger, MM; Duerr, EM; Ebert, MP; Galle, PR; Geissler, M; Kaiser, AK; Kanzler, S; Kolligs, FT; Lammert, F; Lindig, U; Lohse, A; Lubomierski, N; Maderer, A; Moehler, M; Sauvigny, C; Schadmand-Fischer, S; Schimanski, C; Schütz, M; Trojan, J; Wachtlin, D; Woerns, M; Zimmermann, S, 2014) |
| "This study evaluated the addition of sorafenib to gemcitabine and cisplatin in biliary adenocarcinoma first-line therapy." | 9.17 | A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. ( Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH, 2013) |
| "We conducted a phase II trial of single-agent sorafenib in patients with advanced biliary tract carcinoma." | 9.14 | Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. ( Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S, 2010) |
| "Sorafenib and erlotinib were administered continuously at 400 mg BID and 100 mg daily, respectively." | 6.79 | S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. ( Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB, 2014) |
| "Sorafenib was administered at 400 mg po twice daily continuously." | 6.77 | SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. ( Ben-Josef, E; Blanke, CD; El-Khoueiry, AB; Eng, C; Gold, PJ; Govindarajan, R; Hamilton, RD; Lenz, HJ; Rankin, CJ, 2012) |
| "Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study." | 5.19 | Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. ( Berie, L; Denzer, U; Distelrath, A; Dollinger, MM; Duerr, EM; Ebert, MP; Galle, PR; Geissler, M; Kaiser, AK; Kanzler, S; Kolligs, FT; Lammert, F; Lindig, U; Lohse, A; Lubomierski, N; Maderer, A; Moehler, M; Sauvigny, C; Schadmand-Fischer, S; Schimanski, C; Schütz, M; Trojan, J; Wachtlin, D; Woerns, M; Zimmermann, S, 2014) |
| "This study evaluated the addition of sorafenib to gemcitabine and cisplatin in biliary adenocarcinoma first-line therapy." | 5.17 | A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. ( Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH, 2013) |
| "We conducted a phase II trial of single-agent sorafenib in patients with advanced biliary tract carcinoma." | 5.14 | Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. ( Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S, 2010) |
| "Sorafenib and erlotinib were administered continuously at 400 mg BID and 100 mg daily, respectively." | 2.79 | S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. ( Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB, 2014) |
| "Sorafenib was administered at 400 mg po twice daily continuously." | 2.77 | SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. ( Ben-Josef, E; Blanke, CD; El-Khoueiry, AB; Eng, C; Gold, PJ; Govindarajan, R; Hamilton, RD; Lenz, HJ; Rankin, CJ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Yang, B | 1 |
| Miao, H | 1 |
| Liu, L | 1 |
| Wang, Z | 1 |
| Jiang, C | 1 |
| Yang, Y | 1 |
| Qiu, S | 1 |
| Li, X | 1 |
| Geng, Y | 1 |
| Zhang, Y | 1 |
| Liu, Y | 1 |
| Lee, JK | 1 |
| Capanu, M | 1 |
| O'Reilly, EM | 1 |
| Ma, J | 1 |
| Chou, JF | 1 |
| Shia, J | 1 |
| Katz, SS | 1 |
| Gansukh, B | 1 |
| Reidy-Lagunes, D | 1 |
| Segal, NH | 1 |
| Yu, KH | 1 |
| Chung, KY | 1 |
| Saltz, LB | 1 |
| Abou-Alfa, GK | 1 |
| El-Khoueiry, AB | 2 |
| Rankin, C | 1 |
| Siegel, AB | 1 |
| Iqbal, S | 1 |
| Gong, IY | 1 |
| Micetich, KC | 1 |
| Kayaleh, OR | 1 |
| Lenz, HJ | 2 |
| Blanke, CD | 2 |
| Moehler, M | 1 |
| Maderer, A | 1 |
| Schimanski, C | 1 |
| Kanzler, S | 1 |
| Denzer, U | 1 |
| Kolligs, FT | 1 |
| Ebert, MP | 1 |
| Distelrath, A | 1 |
| Geissler, M | 1 |
| Trojan, J | 1 |
| Schütz, M | 1 |
| Berie, L | 1 |
| Sauvigny, C | 1 |
| Lammert, F | 1 |
| Lohse, A | 1 |
| Dollinger, MM | 1 |
| Lindig, U | 1 |
| Duerr, EM | 1 |
| Lubomierski, N | 1 |
| Zimmermann, S | 1 |
| Wachtlin, D | 1 |
| Kaiser, AK | 1 |
| Schadmand-Fischer, S | 1 |
| Galle, PR | 1 |
| Woerns, M | 1 |
| Bengala, C | 1 |
| Bertolini, F | 1 |
| Malavasi, N | 1 |
| Boni, C | 1 |
| Aitini, E | 1 |
| Dealis, C | 1 |
| Zironi, S | 1 |
| Depenni, R | 1 |
| Fontana, A | 1 |
| Del Giovane, C | 1 |
| Luppi, G | 1 |
| Conte, P | 1 |
| Rankin, CJ | 1 |
| Ben-Josef, E | 1 |
| Gold, PJ | 1 |
| Hamilton, RD | 1 |
| Govindarajan, R | 1 |
| Eng, C | 1 |
| Faris, JE | 1 |
| Zhu, AX | 1 |
1 review available for niacinamide and Gallbladder Neoplasms
| Article | Year |
|---|---|
Targeted therapy for biliary tract cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
5 trials available for niacinamide and Gallbladder Neoplasms
| Article | Year |
|---|---|
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile | 2013 |
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile D | 2014 |
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2014 |
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Bilia | 2010 |
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Diseas | 2012 |
1 other study available for niacinamide and Gallbladder Neoplasms
| Article | Year |
|---|---|
Nicotinamide N -methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma.
Topics: Gallbladder Neoplasms; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-6; Leuk | 2023 |